While tackling sepsis is our urgent first goal, our research shows strong promise for XGal-3® in other critical areas impacting millions:

• Chronic Kidney Disease: A huge challenge affecting 37 million Americans ($84B market).
• Cancer Immunotherapy: Aiming to boost treatment effectiveness ($24.6B market).
• Liver and Lung Fibrosis: Addressing devastating conditions ($100B market).
• Neurodegenerative Conditions: Early research even points towards Alzheimer's.

When you invest in Eliaz Therapeutics, you're backing more than a single treatment. You're supporting a versatile platform with the potential to change lives across numerous challenging diseases.

Join us in advancing this powerful platform technology!